CA2837247C - 1 , 2 , 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases - Google Patents
1 , 2 , 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases Download PDFInfo
- Publication number
- CA2837247C CA2837247C CA2837247A CA2837247A CA2837247C CA 2837247 C CA2837247 C CA 2837247C CA 2837247 A CA2837247 A CA 2837247A CA 2837247 A CA2837247 A CA 2837247A CA 2837247 C CA2837247 C CA 2837247C
- Authority
- CA
- Canada
- Prior art keywords
- thiadiazol
- phenyl
- piperazine
- chloro
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11172324.3 | 2011-07-01 | ||
| EP11172324 | 2011-07-01 | ||
| PCT/EP2012/062778 WO2013004642A1 (en) | 2011-07-01 | 2012-06-29 | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2837247A1 CA2837247A1 (en) | 2013-01-10 |
| CA2837247C true CA2837247C (en) | 2020-03-31 |
Family
ID=46545347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2837247A Active CA2837247C (en) | 2011-07-01 | 2012-06-29 | 1 , 2 , 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9023852B2 (enExample) |
| EP (1) | EP2726470B1 (enExample) |
| JP (1) | JP5972367B2 (enExample) |
| CN (1) | CN103619825B (enExample) |
| AU (1) | AU2012280420B2 (enExample) |
| CA (1) | CA2837247C (enExample) |
| ES (1) | ES2540956T3 (enExample) |
| PL (1) | PL2726470T3 (enExample) |
| WO (1) | WO2013004642A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6051218B2 (ja) * | 2011-08-17 | 2016-12-27 | リマインド・ナムローゼ・フエンノートシャップＲｅｍｙｎｄ Ｎｖ | アルツハイマー病等のタウオパチーの治療に有用なピペラジンチアジアゾール誘導体 |
| US10562869B2 (en) | 2014-03-17 | 2020-02-18 | Remynd Nv | Oxadiazole compounds |
| MX383697B (es) * | 2016-06-23 | 2025-03-14 | St Jude Childrens Res Hospital Inc | Moduladores de moleculas peque?as de pantotenato cinasas |
| EP3529245A4 (en) * | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| MX2020006754A (es) | 2017-12-27 | 2021-01-29 | St Jude Childrens Res Hospital Inc | Moduladores de molécula pequeña de pantotenato-cinasas. |
| WO2019133632A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital | Methods of treating disorders associated with castor |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN122206438A (zh) | 2023-11-13 | 2026-06-12 | 瑞敏德股份有限公司 | 用于在预防和/或治疗神经退行性障碍中使用的隔膜蛋白6的调节剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000051999A1 (en) * | 1999-03-03 | 2000-09-08 | American Home Products Corporation | New diazole derivatives as serotonergic agents |
| EP1175416B1 (en) * | 1999-04-26 | 2003-07-16 | Neurosearch A/S | Heteroaryl diazacycloalkanes, their preparation and use |
| DE102004032567A1 (de) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituierte 1-Propiolyl-piperazine |
| US7541359B2 (en) * | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| GB0602335D0 (en) * | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
| AR059355A1 (es) * | 2006-02-07 | 2008-03-26 | Wyeth Corp | Inhibidores de 11-beta hsd1 |
-
2012
- 2012-06-29 WO PCT/EP2012/062778 patent/WO2013004642A1/en not_active Ceased
- 2012-06-29 PL PL12737238T patent/PL2726470T3/pl unknown
- 2012-06-29 EP EP20120737238 patent/EP2726470B1/en active Active
- 2012-06-29 AU AU2012280420A patent/AU2012280420B2/en not_active Ceased
- 2012-06-29 CN CN201280030881.0A patent/CN103619825B/zh not_active Expired - Fee Related
- 2012-06-29 US US14/127,779 patent/US9023852B2/en active Active
- 2012-06-29 CA CA2837247A patent/CA2837247C/en active Active
- 2012-06-29 ES ES12737238.1T patent/ES2540956T3/es active Active
- 2012-06-29 JP JP2014517749A patent/JP5972367B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2837247A1 (en) | 2013-01-10 |
| WO2013004642A1 (en) | 2013-01-10 |
| ES2540956T3 (es) | 2015-07-15 |
| US20140128404A1 (en) | 2014-05-08 |
| JP2014518240A (ja) | 2014-07-28 |
| AU2012280420A1 (en) | 2013-12-12 |
| CN103619825B (zh) | 2015-10-14 |
| AU2012280420B2 (en) | 2017-01-05 |
| EP2726470B1 (en) | 2015-04-29 |
| US9023852B2 (en) | 2015-05-05 |
| CN103619825A (zh) | 2014-03-05 |
| JP5972367B2 (ja) | 2016-08-17 |
| PL2726470T3 (pl) | 2015-09-30 |
| HK1192726A1 (en) | 2014-08-29 |
| EP2726470A1 (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012280420B2 (en) | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases | |
| JP5006799B2 (ja) | 神経疾患及び精神神経疾患の処置用のグリシントランスポーター１（ｇｌｙｔ−１）阻害剤としての［４−（ヘテロアリール）ピペラジン−１−イル］−（２，５−置換フェニル）−メタノン誘導体 | |
| CA2747419C (en) | Sulfonamide derivatives | |
| JP2007512230A (ja) | プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物 | |
| CA2952920A1 (en) | Mitotic kinesin inhibitors and methods of use thereof | |
| JPWO2004092147A1 (ja) | Ｍ期キネシン阻害剤 | |
| ZA200204349B (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases. | |
| CA2841037C (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease | |
| JPH0568451B2 (enExample) | ||
| CA3157600A1 (en) | Quinazoline derivatives as lpa receptor 2 inhibitors | |
| EP4073069B1 (en) | Aromatic amido derivatives as lpa receptor 2 inhibitors | |
| JPWO2004111023A1 (ja) | チアジアゾリン−１−オキシド誘導体 | |
| CA3157595A1 (en) | Thienopyrimidine derivatives as lpa receptor 2 inhibitors | |
| HK1192726B (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | |
| CA3212918A1 (en) | 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors | |
| CN1898237B (zh) | 嘧啶-4-基-3,4-硫酮化合物及其治疗用途 | |
| HK1192848B (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170428 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251014 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260210 |